


# Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China

## Graphical Abstract



## Authors

Jing Lu, Louis du Plessis, Zhe Liu, ..., Jayna Raghvani, Oliver G. Pybus, Changwen Ke

## Correspondence

oliver.pybus@zoo.ox.ac.uk (O.G.P.),  
kecw1965@aliyun.com (C.K.)

## In Brief

Genomic and epidemiological analyses provide insights into how COVID-19 was contained in China's most populous province using a combination of surveillance and travel restriction measures.

## Highlights

- 1.6 million tests identified 1,388 SARS-CoV-2 infections in Guangdong by 19 March
- Virus genomes can be recovered using a variety of sequencing approaches
- Analyses reveal multiple viral importations with limited local transmission
- Effective control measures helped reduce and eliminate chains of viral transmission



## Article

# Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China

Jing Lu,<sup>1,2,10</sup> Louis du Plessis,<sup>3,10</sup> Zhe Liu,<sup>1,2,10</sup> Verity Hill,<sup>4,10</sup> Min Kang,<sup>2</sup> Huifang Lin,<sup>1,2</sup> Jiufeng Sun,<sup>1,2</sup> Sarah François,<sup>3</sup> Moritz U.G. Kraemer,<sup>3</sup> Nuno R. Faria,<sup>3</sup> John T. McCrone,<sup>4</sup> Jinju Peng,<sup>1,2</sup> Qianling Xiong,<sup>1,2</sup> Runyu Yuan,<sup>1,2</sup> Lilian Zeng,<sup>1,2</sup> Pingping Zhou,<sup>1,2</sup> Chumin Liang,<sup>1,2</sup> Lina Yi,<sup>1,2</sup> Jun Liu,<sup>2</sup> Jianpeng Xiao,<sup>1,2</sup> Jianxiong Hu,<sup>1,2</sup> Tao Liu,<sup>1,2</sup> Wenjun Ma,<sup>1,2</sup> Wei Li,<sup>2</sup> Juan Su,<sup>2</sup> Huanying Zheng,<sup>2</sup> Bo Peng,<sup>5</sup> Shisong Fang,<sup>5</sup> Wenzhe Su,<sup>6</sup> Kuibiao Li,<sup>6</sup> Ruilin Sun,<sup>7</sup> Ru Bai,<sup>7</sup> Xi Tang,<sup>8</sup> Minfeng Liang,<sup>8</sup> Josh Quick,<sup>9</sup> Tie Song,<sup>2</sup> Andrew Rambaut,<sup>4</sup> Nick Loman,<sup>9</sup> Jayna Raghwani,<sup>3</sup> Oliver G. Pybus,<sup>3,11,\*</sup> and Changwen Ke<sup>2,\*</sup>

<sup>1</sup>Guangdong Provincial Institution of Public Health, Guangzhou 511430, China

<sup>2</sup>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China

<sup>3</sup>Department of Zoology, University of Oxford, Oxford OX1 3SZ, UK

<sup>4</sup>Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH8 9YL, UK

<sup>5</sup>Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China

<sup>6</sup>Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China

<sup>7</sup>Guangdong Provincial Second People's Hospital, Guangzhou 510320, China

<sup>8</sup>Foshan First People's Hospital, Foshan 528000, China

<sup>9</sup>Institute of Microbiology and Infection, University of Birmingham, Birmingham B15 2TT, UK

<sup>10</sup>These authors contributed equally

<sup>11</sup>Lead Contact

\*Correspondence: [oliver.pybus@zoo.ox.ac.uk](mailto:oliver.pybus@zoo.ox.ac.uk) (O.G.P.), [kecw1965@aliyun.com](mailto:kecw1965@aliyun.com) (C.K.)

<https://doi.org/10.1016/j.cell.2020.04.023>

## SUMMARY

Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 infection and was first reported in central China in December 2019. Extensive molecular surveillance in Guangdong, China's most populous province, during early 2020 resulted in 1,388 reported RNA-positive cases from 1.6 million tests. In order to understand the molecular epidemiology and genetic diversity of SARS-CoV-2 in China, we generated 53 genomes from infected individuals in Guangdong using a combination of metagenomic sequencing and tiling amplicon approaches. Combined epidemiological and phylogenetic analyses indicate multiple independent introductions to Guangdong, although phylogenetic clustering is uncertain because of low virus genetic variation early in the pandemic. Our results illustrate how the timing, size, and duration of putative local transmission chains were constrained by national travel restrictions and by the province's large-scale intensive surveillance and intervention measures. Despite these successes, COVID-19 surveillance in Guangdong is still required, because the number of cases imported from other countries has increased.


## INTRODUCTION

A new virus-associated disease, coronavirus disease 2019 (COVID-19), was initially reported in China on 30<sup>th</sup> December 2019 (Wu et al., 2020). The causative agent of COVID-19 is the novel human coronavirus SARS-CoV-2 (Wu et al., 2020; Zhou et al., 2020), and, as of 24<sup>th</sup> March 2020, there have been 372,757 confirmed infections and 16,231 deaths reported worldwide (World Health Organization, 2020). In China, the COVID-19 epidemic grew exponentially during January 2020, peaking on 12<sup>th</sup> February 2020 with 15,153 newly confirmed cases per day. One month later, reported COVID-19 cases in China dropped to ~20 per day, indicating the epidemic there was contained. However, the number of cases reported outside of China has risen exponentially since the second half of February 2020. By

11<sup>th</sup> March 2020, the day that the World Health Organization (WHO) announced COVID-19 to be a new pandemic, 37,371 cases had been reported outside of China (World Health Organization, 2020).

Guangdong Province and the Pearl River Delta Metropolitan Region contain some of the world's largest and most densely populated urban areas. Guangdong is the most populous province of China (113 m people) and contains many large cities including Guangzhou (12 m), Shenzhen (10 m), Dongguan (8 m), and Foshan (7 m). The province has strong transportation links to Hubei Province, where the first cases of COVID-19 were reported. The Wuhan-Guangzhou high-speed railway has been estimated to transfer 0.1–0.2 million passengers per day during the spring festival period, which started on 10<sup>th</sup> January 2020. By 19<sup>th</sup> March 2020, Guangdong had





**Figure 1. Summary of the COVID-19 Epidemic in Guangdong Province, China**

(A) Time series of the 1,388 laboratory-confirmed COVID-19 cases in Guangdong until 19<sup>th</sup> March 2020, by date of onset of illness. Cases are classified according to their likely exposure histories (see inset and main text). The dashed lines indicate the date the first Guangdong case was detected (19<sup>th</sup> January 2020) and the shutdown of travel from Wuhan (23<sup>rd</sup> January 2020). An overview of testing and surveillance strategies at different stages of the epidemic is illustrated below the time series, on the same timescale.

(B) Geographic distribution of COVID-19 cases and human population density among the 21 prefecture-level divisions of Guangdong Province. See also Figure S1.

1,388 confirmed cases of COVID-19, the highest in China outside of Hubei Province.


Understanding the evolution and transmission patterns of a virus after it enters a new population is crucial for designing effective strategies for disease control and prevention (Faria et al., 2018; Grubaugh et al., 2017; Ladner et al., 2019). In this study, we combine genetic and epidemiological data to investigate the genetic diversity, evolution, and epidemiology of SARS-CoV-2 in Guangdong Province. We generated virus genome sequences from 53 patients in Guangdong using both metagenomic sequencing and multiplex PCR amplification followed by nanopore sequencing. Through phylogenetic analysis, interpreted in the context of available epidemiological information, we sought to investigate the timing and relative contributions of imported cases versus local transmission, the nature of genetically distinct transmission chains within Guangdong, and how the emergency response in Guangdong was reflected in the reduction and elimination of these transmission chains. Our results may provide valuable information for implementing and interpreting genomic surveillance of COVID-19 in other regions.

## RESULTS

Enhanced surveillance was launched in all clinics in Guangdong province following the first reports of patients with undiagnosed pneumonia on 30<sup>th</sup> December 2019. Initially, screening and sampling for SARS-CoV-2 was targeted toward patients with fever and respiratory symptoms and those who had a history of travel in the 14 days before the date of symptom onset. The first detected case in Guangdong had symptom onset on 1<sup>st</sup> January and was reported on 19<sup>th</sup> January 2020 (Kang et al., 2020). COVID-19 cases in Guangdong grew until early February 2020

(peaking at >100 cases per day) and declined thereafter (Figure 1A). After 22<sup>nd</sup> February 2020, the daily number of locally infected reported cases in Guangdong did not exceed one. However, since the beginning of March 2020 COVID-19 cases imported into Guangdong from abroad have been detected with increasing frequency. As of 26<sup>th</sup> March 2020, a total of 102 imported cases were reported from 19 different countries (Figure 1A), highlighting the risk that local COVID-19 transmission could reignite in China.

Different surveillance strategies were applied during the epidemic in Guangdong (Figure 1A; STAR Methods). More intensive surveillance was initiated on 30<sup>th</sup> January 2020 in response to the Spring Festival period, which results in greater mobility among regions and provinces in China (Kraemer et al., 2020; Tian et al., 2020) and because asymptomatic COVID-19 cases had been reported (Guan et al., 2020). This included monitoring (1) all travelers returning from Hubei or other regions with high epidemic activity, (2) their close contacts, and (3) all hospitalized patients in clinics, including those without fever or respiratory symptoms, regardless of their exposure history. Approximately 1.35 million samples were screened by six third-party institutions between 30<sup>th</sup> January and 15<sup>th</sup> March 2020. Surveillance commenced at Guangdong airports in early March, following the growth of COVID-19 outbreaks outside of China. In total, ~1.6 million tests were performed by 19<sup>th</sup> March 2020, identifying 1,388 SARS-CoV-2 positive cases in 20 of 21 prefectures in Guangdong Province (Figure 1B). Around a quarter of cases (336) were judged to be linked to local transmission and two-thirds (1,014) had a likely exposure history in Hubei (see STAR Methods). For locally infected cases, 181 (53%) were linked to transmission among household members. More than half of the reported cases (60%) were from the cities of Shenzhen



**Figure 2. Profile of SARS-CoV-2 Genome Sequences from Guangdong Province, China**

(A) Plot of SARS-CoV-2 genome coverage against real-time reverse transcription Ct value for the 53 genome sequences reported here. Each sequence is colored by sequencing approach: blue, BGI metagenomic sequencing; orange, multiplex PCR nanopore sequencing; green, Illumina metagenomic sequencing.

(B) Real-time reverse transcription PCR Ct values for different sample types.

(C) Real-time reverse transcription PCR Ct values for samples from patients with different disease severity; the “mild” category includes 2 asymptomatic cases. (D) Genome coverage map for the 53 genomes reported here, ordered by % genome coverage. Single nucleotide polymorphisms (with respect to the reference genome MN908947.3) are colored in red. Each genome is colored according to the sequencing approach used.

(E) Genomic structure of SARS-CoV-2 and the genomic location and frequency of single nucleotide polymorphisms (with respect to the reference genome MN908947.3) among our 53 sequences. These mutations correspond to the red lines in (D).

See also [Figure S2](#), [Table S1](#), and [Data S1](#).


and Guangzhou ([Figure 1B](#)). We note that the number of detected cases will be less than the true number of infections, although the degree of under-reporting is unknown. Surveillance was targeted toward travelers, hence these data may overestimate the proportion of travel-associated cases.

To understand the genetic structure of the COVID-19 outbreak in Guangdong, we generated near-complete and partial genomes from 53 COVID-19 patients in Guangdong Province. The genomes were generated by a combination of metagenomic sequencing and multiplex PCR amplification followed by nanopore sequencing on a MinION device (see [STAR Methods](#)). Sequence sampling dates ranged from 30<sup>th</sup> January to 28<sup>th</sup> February 2020 ([Figure S1](#)).

Sequencing was performed on 79 clinical samples (throat swabs, n = 32; anal swabs, n = 24; nasopharyngeal swabs, n = 10; sputum, n = 13) collected from 62 patients with varying disease symptoms, ranging from asymptomatic to very severe (see [STAR Methods](#)). Real-time reverse transcription PCR Ct

(cycle threshold) values of these samples ranged from 19 to 40.86. [Figure 2A](#) displays the Ct values for the 53 samples with >50% genome coverage for which we report whole and partial genome sequences (see [Figure S2](#) for details of all 79 samples). When Ct values are <30, sequence reads covered ~90% or more of the reference genome (GenBank: MN908947.3) irrespective of the amplification and sequencing approach used (see [STAR Methods](#)). However, genome coverage declined for samples with Ct >30 ([Figure S2](#)). Using a Kruskal-Wallis rank-sum test we found an association between sample Ct values and sample type ([Figure 2B](#);  $p < 0.001$ ), and sample Ct values and disease severity ([Figure 2C](#);  $p = 0.03$ ) (see also [Liu et al., 2020](#)), however, we note that sampling was not undertaken with these hypotheses in mind.

Sequences generated with nanopore sequencing indicate common regions of low coverage ([Figure 2D](#)), indicating that the version 1 primer set used here did not amplify some regions efficiently. Efficient primer binding may have been prevented due



**Figure 3. Phylogenetic Analyses of SARS-CoV-2 Genome Sequences from Guangdong Province, China**

(A) Estimated maximum likelihood phylogeny of SARS-CoV-2 sequences from Guangdong (red circles) and genomes from other countries and provinces (not circled). The axis is in units of nucleotide changes from the inferred root sequence. A phylogenetic bootstrap analysis was not performed due to the low number of phylogenetically informative sites and the number of missing bases (N) in the alignment. The position of clusters A–E discussed in main text are highlighted with red boxes and labeled.

(B) Visualization of the corresponding time-scaled maximum clade credibility tree. Sequences from Guangdong and their terminal branches are in red and those from other locations in gray. The clusters (A–E) discussed in main text are highlighted with boxes and labeled. All nodes with posterior probabilities <0.5 have been collapsed into polytomies and their range of divergence dates are illustrated as shaded gray expanses.

See also [Figures S3, S4, and S5](#).

to genetic divergence from the reference genome (MN908947.3). An alternative explanation is the interaction between two particular primers, resulting in primer dimer formation (Itokawa et al., 2020). After completion of this study, the primers have been redesigned to address these issues and improve coverage (Quick 2020). Shared and unique single nucleotide polymorphisms (SNPs) were observed at 97 sites across the SARS-CoV-2 genome (Figures 2D and 2E), with 77 SNPs present in only one genome. Three SNPs were present in >10 genomes: (C8782T, C21711T, and T28144C). When compared to 49 previously released genomes from Hubei and Guangdong, 118 SNPs are present in only one genome and these three SNPs are still the only variants shared among >10 genomes (Data S1).


To understand the genetic diversity of the SARS-CoV-2 epidemic in Guangdong, we performed phylogenetic analyses using maximum likelihood and Bayesian molecular clock approaches. We added our new virus genomes from Guangdong to 177 publicly available sequences, which includes 73 sequences from China, 17 of which were previously reported Guangdong genomes. The final alignment comprised 250 sequences and increased the number of SARS-CoV-2 sequences from China by ~60% when our data were submitted to GISAID (on 9<sup>th</sup> March).

The estimated maximum likelihood (ML) phylogeny is shown in Figure 3A. The SARS-CoV-2 sequences from Guangdong (red) are interspersed with viral lineages sampled from other Chinese provinces and other countries (gray). This pattern agrees with the epidemiological time series in Figure 1A, indicating that most detected cases were linked to travel rather than local community

transmission. Despite this, there were a number of instances where sequences from Guangdong appeared to cluster together, sometimes with sequences sampled from other regions. To explore these lineages in more detail, we performed a Bayesian molecular clock analysis that places the phylogenetic history of the genomes on an estimated timescale. A summary visualization of the maximum clade credibility tree from that analysis is shown in Figure 3B and is largely congruent with the ML tree. The current low genetic diversity of SARS-CoV-2 genomes worldwide means that most internal nodes have very low posterior probabilities; we caution that no conclusions should be drawn from these branching events as they will be informed by the phylogenetic prior distribution rather than variable nucleotide sites (Figure 3A). Nevertheless, five clusters (denoted A–E) containing Guangdong sequences had posterior probability support of >80% (i.e., their sequences grouped monophyletically in >80% of trees in the posterior sample; Figure 3B). These clusters were also observed in the ML phylogeny (Figure 3A). Some included only sequences sampled in Guangdong (A, B), others included sequences sampled in other countries and provinces (C, D, E).

From the molecular clock analysis, we were able to estimate the times of the most recent common ancestor (tMRCA) of clusters A–E. We found that SARS-CoV-2 lineages were imported multiple times into Guangdong during the second half of January 2020 (Figure 4). Three clusters (C, D, E) have earlier tMRCAs that coincide with the start of the Guangdong epidemic and two (A, B) have later tMRCAs, around the time of the epidemic peak in the province (Figure 4). The average time between the tMRCA and the earliest





**Figure 4. Molecular Clock Analysis of the Five Phylogenetic Clusters of Guangdong Sequences that Were Supported with Posterior Probabilities >80% in Bayesian Phylogenetic Analysis**

(A) Daily number of local and imported COVID-19 cases in Guangdong province. The first reported case in Guangdong (January 19) and the shutdown of travel from Wuhan (January 23) are indicated by dashed lines.

(B) Posterior distributions of the tMRCA of the five phylogenetic clusters (A–E) from the molecular clock analysis (Figure 3B). Distributions are truncated at the upper and lower limits of the 95% HPD intervals; the vertical red lines indicate median estimates. Blue shading and horizontal red lines indicate the sampling period over which genomes in each cluster were collected. Dots indicate the collection dates of genomes, colored by sampling location (red, Guangdong; gray, other).

See also Table S1.

sequence collection date in each cluster was approximately 10.25 days. The observed duration of each phylogenetic cluster (tMRCA to most recently sampled sequence) ranged from 9.49 (cluster B) to 45.2 (cluster D) days. The clusters with earlier tMRCA contain more sequences from travelers sampled outside of China, possibly reflecting a decrease in air passenger travel from Guangdong after January 2020 (Flihtadar24, 2020). The median tMRCA estimate of the COVID-19 pandemic was 1<sup>st</sup> December 2019 (95% HPD 15<sup>th</sup> November to 13<sup>th</sup> December 2019; Figure 4), consistent with previous analyses (Rambaut, 2020).

The apparent clusters of Guangdong sequences require careful interpretation because of the relative undersampling of SARS-CoV-2 genomes from other Chinese provinces, including Hubei. Specifically, it is known that undersampling of regions with high incidence can lead to phylogenetic analyses underestimating the number of introductions into recipient locations and overestimating the size and duration of transmission chains in those recipient locations (Grubaugh et al., 2017; Kraemer et al., 2018). For example, the largest Guangdong phylogenetic cluster (denoted A in Figures 3 and 4) comprises 8 sequences, none of which are placed at the root of the cluster, and it is tempting to conclude that the entire cluster derived from community transmission within Guangdong. However, 6 of the 8 genomes reported travel from Hubei and therefore the cluster in fact represents multiple SARS-

CoV-2 introductions into Guangdong, with dates of symptom onset around or shortly after the shutdown of travel from Wuhan (Figure 4).

## DISCUSSION

Our analyses of the genomic epidemiology of SARS-CoV-2 in Guangdong province indicate that, following the first COVID-19 case detected in early January, most infections were the result of virus importation from elsewhere, and that chains of local transmission were limited in size and duration. This suggests that the large-scale surveillance and intervention measures implemented in Guangdong were effective in interrupting community transmission in a densely populated urban region, ultimately containing the epidemic and limiting the potential for dissemination to other regions (Leung et al., 2020). However, vigilance is still required as there remains a risk that SARS-CoV-2 transmission could reignite in Guangdong following the recent increase in the number of COVID-19 cases imported to China from other countries.

The results also suggest that analyses of phylogenetic structure during the early phase of the pandemic should be interpreted carefully. The number of mutations that define phylogenetic lineages are small (often one), and may be similar to the number of sequence differences arising from errors introduced during reverse transcription, PCR amplification, or sequencing. Bayesian estimates of divergence times (Rannala and Yang, 1996), such as the tMRCA of the pandemic, are based on aggregate numbers of mutations and informed by dense sampling through time, and are thus expected to be more robust. Further, the low and variable sampling of COVID-19 cases among different regions makes it challenging to evaluate phylogenetic clusters that comprise cases from a single region; although such clusters could indeed represent local transmission, our results show they can also include multiple introductions from a genomically undersampled location. Therefore, as with all phylogenetic analyses, the SARS-CoV-2 genomes must be interpreted in the context of all available epidemiological information.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Ethics
  - Sample collection, clinical surveillance and epidemiological data
  - Further details of surveillance of COVID-19 in Guangdong, China
  - Further details of sequence sample collection
  - Clinical classification of COVID-19 cases
- METHOD DETAILS

- Virus amplification and sequencing
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Virus genome assembly
  - Phylogenetic analysis

## SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.cell.2020.04.023>.

## ACKNOWLEDGMENTS

We gratefully acknowledge the efforts of local CDCs, hospitals, and the third-party detection institutions in epidemiological investigations, sample collection, and detection. We would like to thank all the authors who have kindly deposited and shared genome data on GISAID. A table with genome sequence acknowledgments can be found in Table S1.4. This work was supported by grants from Guangdong Provincial Novel Coronavirus Scientific and Technological Project (2020111107001), Science and Technology Planning Project of Guangdong (2018B020207006), and the Key Research and Development Program of Guangdong Province (2019B111103001). O.G.P., M.U.G.K., and L.d.P. were supported by the Oxford Martin School. V.H. is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/M010996/1). N.R.F. acknowledges funding from a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z) and from a Medical Research Council and FAPESP award (MR/S0195/1). J.Q. is funded by a UK Research and Innovation Future Leaders Fellowship. A.R. is supported by the European Research Council (725422-ReservoirDOCS). This work was supported by the Wellcome Trust ARTIC network (Collaborators Award206298/Z/17/Z).

## AUTHOR CONTRIBUTIONS

J. Lu., O.G.P., and C.K. designed the study. J. Lu, Z.L., H.L., J. Sun, J.P., Q.X., R.Y., L.Z., P.Z., C.L., W.L., J. Su, H.Z., B.P., S.F., W.S., K.L., R.S., R.B., X.T., M.L., and T.S. undertook fieldwork and experiments. L.d.P., J. Lu, Z.L., V.H., S.F., J.T.M., L.Y., J.Q., A.R., N.L., J.R., and O.G.P. performed genetic analyses. L.d.P., M.K., M.U.G.K., J. Liu, J.X., J.H., T.L., and W.M. performed epidemiological analyses. J.R., J. Lu, L.d.P., V.H., N.R.F., and O.G.P. wrote the manuscript. L.d.P., J. Lu, V.H., M.U.G.K., A.R., J.R., and O.G.P. edited the manuscript. All authors were involved in coordination, collection, processing, sequencing, and/or bioinformatics of clinical samples. All authors read and approved the contents of the manuscript.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: March 27, 2020

Revised: April 9, 2020

Accepted: April 14, 2020

Published: April 30, 2020

## REFERENCES

- Ayres, D.L., Darling, A., Zwickl, D.J., Beerli, P., Holder, M.T., Lewis, P.O., Huel- senbeck, J.P., Ronquist, F., Swofford, D.L., Cummings, M.P., et al. (2012). BEAGLE: an application programming interface and high-performance computing library for statistical phylogenetics. *Syst. Biol.* 61, 170–173.
- Faria, N.R., Kraemer, M.U.G., Hill, S.C., Goes de Jesus, J., Aguiar, R.S., Iani, F.C.M., Xavier, J., Quick, J., du Plessis, L., Dellicour, S., et al. (2018). Genomic and epidemiological monitoring of yellow fever virus transmission potential. *Science* 361, 894–899.
- Ferreira, M.A., and Suchard, M.A. (2008). Bayesian analysis of elapsed times in continuous-time Markov chains. *Can. J. Stat.* 36, 355–368.
- Flightradar24 (2020). Air traffic at China's busiest airports down 80% since the beginning of the year. <https://www.flightradar24.com/blog/air-traffic-at-chinas-busiest-airports-down-80-since-the-beginning-of-the-year/>.
- Grubaugh, N.D., Ladner, J.T., Kraemer, M.U.G., Dudas, G., Tan, A.L., Gangavarapu, K., Wiley, M.R., White, S., Thézé, J., Magnani, D.M., et al. (2017). Genomic epidemiology reveals multiple introductions of Zika virus into the United States. *Nature* 546, 401–405.
- Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., et al.; China Medical Treatment Expert Group for Covid-19 (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *N. Engl. J. Med.* Published online February 28, 2020. <https://doi.org/10.1056/NEJMoa2002032>.
- Guindon, S., Dufayard, J.F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O. (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst. Biol.* 59, 307–321.
- Hasegawa, M., Kishino, H., and Yano, T. (1985). Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. *J. Mol. Evol.* 22, 160–174.
- Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R., and Kuroda, M. (2020). A proposal of an alternative primer for the ARTIC Network's multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing. *bioRxiv*. <https://doi.org/10.1101/2020.03.10.985150>.
- Kang, M., Wu, Jie, Ma, Wenjun, He, Jianfeng, Lu, Jing, Liu, Tao, Li, Baisheng, Mei, Shuijiang, Ruan, Feng, Lin, Lifeng, et al. (2020). Evidence and characteristics of human-to-human transmission of SARS-CoV-2. *medRxiv*. Published online February 17, 2020. <https://doi.org/10.1101/2020.02.03.20019141>.
- Katoh, K., and Standley, D.M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* 30, 772–780.
- Kraemer, M.U.G., Cummings, D.A.T., Funk, S., Reiner, R.C., Faria, N.R., Pybus, O.G., and Cauchemez, S. (2018). Reconstruction and prediction of viral disease epidemics. *Epidemiol. Infect.* Nov 5, 1–7.
- Kraemer, M.U., Yang, C.-H., Gutierrez, B., Wu, C.-H., Klein, B., Pigott, D.M., Open COVID-19 Data Working Group, Plessis, P., Faria, N.R., Li, R., et al. (2020). The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science*, eabb4218.
- Ladner, J.T., Grubaugh, N.D., Pybus, O.G., and Andersen, K.G. (2019). Precision epidemiology for infectious disease control. *Nat. Med.* 25, 206–211.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359.
- Leung, K., Wu, J.T., Liu, D., and Leung, G.M. (2020). First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *Lancet*. Published online April 8, 2020. [https://doi.org/10.1016/S0140-6736\(20\)30746-7](https://doi.org/10.1016/S0140-6736(20)30746-7).
- Li, H. (2018). Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* 34, 3094–3100.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- Liu, Y., Yan, L.M., Wan, L., Xiang, T.X., Le, A., Liu, J.M., Peiris, M., Poon, L.L.M., and Zhang, W. (2020). Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* Published online March 19, 2020. [https://doi.org/10.1016/S1473-3099\(20\)30232-2](https://doi.org/10.1016/S1473-3099(20)30232-2).
- Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. J.* 17, 10–12.
- Quick, J. (2020). Artic-ncov2019 primer schemes. [https://github.com/artic-network/artic-ncov2019/tree/master/primer\\_schemes/nCoV-2019/V3](https://github.com/artic-network/artic-ncov2019/tree/master/primer_schemes/nCoV-2019/V3).
- Quick, J., Grubaugh, N.D., Pullan, S.T., Claro, I.M., Smith, A.D., Gangavarapu, K., Oliveira, G., Robles-Sikisaka, R., Rogers, T.F., Beutler, N.A., et al. (2017). Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. *Nat. Protoc.* 12, 1261–1276.

- Rambaut, A. (2020). Phylodynamic Analysis, 176 genomes. <http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356>.
- Rambaut, A., Drummond, A.J., Xie, D., Baele, G., and Suchard, M.A. (2018). Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Syst. Biol.* 67, 901–904.
- Rannala, B., and Yang, Z. (1996). Probability distribution of molecular evolutionary trees: a new method of phylogenetic inference. *J. Mol. Evol.* 43, 304–311.
- Suchard, M.A., Lemey, P., Baele, G., Ayres, D.L., Drummond, A.J., and Rambaut, A. (2018). Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.* 4, vey016.
- Tian, H., Liu, Y., Li, Y., Wu, C.H., Chen, B., Kraemer, M.U.G., Li, B., Cai, J., Xu, B., Yang, Q., et al. (2020). An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. *Science*, eabb6105.
- World Health Organization (2020). Coronavirus disease (COVID-2019) situation reports. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>.
- Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei, Y.Y., et al. (2020). A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265–269.
- Yang, Z. (1994). Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: approximate methods. *J. Mol. Evol.* 39, 306–314.
- Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579, 270–273.



## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins		
Agencourt RNAClean XP beads	Beckman	Cat# A63987
Agencourt AMPure XP	Beckman	Cat# A63881
Critical Commercial Assays		
SpotON sequencing flow cell	Nanopore Technologies	Cat# FLO-MIN106D
Ligation Sequencing Kit	Nanopore Technologies	Cat# SQK-LSK109
Native Barcoding Kit 1D 1-12	Nanopore Technologies	Cat# EXP-NBD104
Native Barcoding Kit 1D 13-24	Nanopore Technologies	Cat# EXP-NBD114
Q5® Hot Start High-Fidelity 2X Master Mix	New England BioLabs	Cat# M0494L
NEBNext Ultra II End repair/dA-tailing Module	New England BioLabs	Cat# E7546L
NEB Blunt/TA Ligase Master Mix	New England BioLabs	Cat# M0367L
NEBNext Quick Ligation Module	New England BioLabs	Cat# E6056L
TURBO DNase	Thermo Fisher	Cat# AM2239
MGIEasy RNA Library Prep kit	MGI	Cat# 1000005274
MGIEasy Circularization Module	MGI	Cat# 1000005260
MGIEasy DNA Adapters-16(Tubes) Kit	MGI	Cat# 1000005284
QIAamp Viral RNA Mini Kit	QIAGEN	Cat# 52904
SMARTer Stranded Total RNA-Seq Kit v2	Clontech	Cat# 634412
SuperScript IV Reverse Transcriptase	Thermo Fisher	Cat# 18090010
Qubit 1X dsDNA HS Assay Kit	Thermo Fisher	Cat# Q33230
Qubit ssDNA Assay Kit	Thermo Fisher	Cat# Q10212
Qubit RNA HS Assay Kit	Thermo Fisher	Cat# Q32852
Deposited Data		
SARs-CoV-2 Genome Sequences	GISAID	EPI_ISL_413850–413902
Software and Algorithms		
Bowtie2 2.3.4.3	JOHNS HOPKINS University	<a href="http://bowtie-bio.sourceforge.net/bowtie2/index.shtml">http://bowtie-bio.sourceforge.net/bowtie2/index.shtml</a>
Samtools 1.3.1	htslib	<a href="http://www.htslib.org">http://www.htslib.org</a>
Artic	ARTIC network	<a href="https://artic.network/ncov-2019">https://artic.network/ncov-2019</a>
Geneious	Biomatters Limited	<a href="https://www.geneious.com">https://www.geneious.com</a>
MAFFT	Katoh and Standley, 2013	<a href="https://mafft.cbrc.jp/alignment/software/">https://mafft.cbrc.jp/alignment/software/</a>
PhyML v3.3	Guindon et al., 2010	<a href="http://www.atgc-montpellier.fr/phyml/">http://www.atgc-montpellier.fr/phyml/</a>
figtreejs-react	N/A	<a href="https://doi.org/10.5281/zenodo.3761848">https://doi.org/10.5281/zenodo.3761848</a>
Guppy Basecalling Software 3.4.5+fb1fbfb	Oxford Nanopore Technologies	<a href="https://community.nanoporetech.com/downloads">https://community.nanoporetech.com/downloads</a>
BEAST v1.10.4	Suchard et al., 2018	<a href="http://beast.community">http://beast.community</a>
R Statistical Computing Software v3.5.1	The R Foundation	<a href="https://www.r-project.org/">https://www.r-project.org/</a>

### RESOURCE AVAILABILITY

#### Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Oliver G Pybus ([oliver.pybus@zoo.ox.ac.uk](mailto:oliver.pybus@zoo.ox.ac.uk)).

### Materials Availability

This study did not generate new unique reagents.

### Data and Code Availability

The accession numbers for the sequences reported in this paper are GISAID: EPI\_ISL\_413850–413902. Code for all figures, tree files, BEAST XML file, BEAST log file, and raw data for [Figures 1, 2, 3, and 4](#) are available at [https://github.com/laduplessis/SARS-CoV-2\\_Guangdong\\_genomic\\_epidemiology](https://github.com/laduplessis/SARS-CoV-2_Guangdong_genomic_epidemiology). A live version of [Figure 3B](#) can be found at [https://laduplessis.github.io/SARS-CoV-2\\_Guangdong\\_genomic\\_epidemiology/](https://laduplessis.github.io/SARS-CoV-2_Guangdong_genomic_epidemiology/).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Ethics

This study was approved by ethics committee of the Center for Disease Control and Prevention of Guangdong Province. Written consent was obtained from patients or their guardian(s) when samples were collected. Patients were informed about the surveillance before providing written consent, and data directly related to disease control were collected and anonymized for analysis.

### Sample collection, clinical surveillance and epidemiological data

After reports of hospitalized cases with undiagnosed, severe pneumonia on December 30<sup>th</sup> 2019, enhanced surveillance was initiated in Guangdong Province to detect suspected infections, especially among cases with recent travel history to Hubei or other epidemic regions over the last 14 days. Suspected COVID-19 cases were screened by 31 designated hospitals, local CDCs in 21 prefecture cities, and 6 third-party detection institutions with commercial real-time reverse transcription PCR (RT-PCR) kits (see below for further details). A subset of positive samples was sent to Guangdong Provincial CDC for verification and further sequencing (see below for further details). Imported infections were defined when confirmed cases had travel history from Hubei or other epidemic regions and did not have close contact with local positive cases in 14 days preceding illness onset. The severity of the disease was classified into mild, moderate, severe, or critical (see below for further details). Further details of clinical case definitions are provided in [STAR Methods](#). Demographic information, date of illness onset, and clinical outcomes of sequenced cases were collected from medical records. The exposure history for each case was obtained through an interview. Information regarding the demographic and geographic distribution of SARS-CoV-2 cases can be found at the website of Health Commission of Guangdong Province (<http://wsjkw.gd.gov.cn/xxgzbdfk/yqtb/>).

### Further details of surveillance of COVID-19 in Guangdong, China

The surveillance scheme in Guangdong included 3 main components:

- Twenty-one prefecture CDCs and 31 designated hospitals.* These are responsible for the suspected cases diagnoses launched on 30<sup>th</sup> December 2019. A suspected case was defined if he/she met one of the following criteria: (i) epidemic history and (ii) fever or respiratory symptoms (see below for further details). Epidemic history included: (i) a history of travel to Wuhan or a person who lived in Wuhan or another region where sustained local transmission existed in the 14 days prior to symptom onset; (ii) contact with a patient with fever/respiratory symptoms from Wuhan or another region where sustained local transmission existed in the 14 days prior to symptom onset; (iii) originated from a cluster of COVID-19 cases or is epidemiologically linked to other COVID-19 cases. As of 15<sup>th</sup> March, 1152 cases were identified through local CDCs and hospitals.
- Six third-party detection institutions.* More intense surveillance was initiated on 30<sup>th</sup> January 2020 in response to the Spring Festival period. This included monitoring (i) all healthy travelers returning from Hubei or other regions with high epidemic activity, (ii) their close contacts, and (iii) all hospitalized patients in clinics, including those without fever or respiratory symptoms, regardless of their exposure history. Approximately 1.35 million samples were screened by six third-party institutions between 30<sup>th</sup> January and 15<sup>th</sup> March 2020 and 199 SARS-CoV-2 positive cases were identified from travelers from Hubei without clinical symptoms (76 in 316,214 or 0.02%), fever clinics (99 in 475,949 or 0.02%), non-fever clinics (3 in 447,702) and their close contacts (14 in 70,509 or 0.02%).
- Airport enhanced surveillance.* Surveillance commenced at Guangdong airports on 9<sup>th</sup> March. As of 15<sup>th</sup>, 3 positive cases were identified from 7,909 diagnoses in Guangzhou Baiyun Airport and a total of 92 imported COVID-19 cases were confirmed as of 26<sup>th</sup> March.

### Further details of sequence sample collection

We collected 58 samples for sequencing from 44 patients (some patients were sampled more than once) in four sentinel hospitals in Guangzhou, Shenzhen and Foshan (Guangzhou Eighth People's Hospital, 9 samples from 9 patients, collected on 30<sup>th</sup> January 2020; Guangdong Second Provincial General Hospital, 33 samples from 19 patients, collected between 31<sup>st</sup> January and 9<sup>th</sup> January 2020; The Third People's Hospital of Shenzhen, 11 samples from 11 patients, collected on 5<sup>th</sup> February 2020; Foshan First People's Hospital, 5 samples from 5 patients, collected between 10<sup>th</sup> February and 12<sup>th</sup> February 2020). These cities recorded the highest number of COVID-19 cases ([Figure 1B](#)). We collected a further 21 samples from 18 patients from a screening project of hospitalized COVID-19

cases in Guangdong, which was launched on 28<sup>th</sup> February. We therefore attempted sequencing on 79 samples from 62 patients (Table S1.1). Because this study focuses on epidemiological questions, we retained only one sequence per patient (the highest quality sequence) and we retained only genomes with > 50% coverage (our quality threshold). This resulted in a final total of 53 genomes.

### Clinical classification of COVID-19 cases

Cases were diagnosed and the severity status was categorized as mild, moderate, severe, and critical according to the Diagnosis and Treatment Scheme for Covid-19 released by the National Health Commission of China (Version 7).

#### Mild cases

The clinical symptoms were mild, and there was no sign of pneumonia on imaging.

#### Moderate cases

Showing fever and respiratory symptoms with radiological findings of pneumonia.

#### Severe cases

Adult cases meeting any of the following criteria:

- i) Respiratory distress ( $\geq 30$  breaths/ min);
- ii) Oxygen saturation  $\leq 93\%$  at rest;
- iii) Arterial partial pressure of oxygen (PaO<sub>2</sub>) / fraction of inspired oxygen (FiO<sub>2</sub>)  $\leq 300$  mmHg (1 mmHg = 0.133 kPa).

In high-altitude areas (at an altitude of over 1,000 m above the sea level), PaO<sub>2</sub>/ FiO<sub>2</sub> shall be corrected by the following formula:

$$\text{PaO}_2/\text{FiO}_2 \times [\text{Atmospheric pressure (mmHg)} / 760]$$

Cases with chest imaging that showed obvious lesion progression within 24-48 hours > 50% shall be managed as severe cases.

Child cases meeting any of the following criteria:

- i) Tachypnea (RR  $\geq 60$  breaths/min for infants aged below 2 months; RR  $\geq 50$  BPM for infants aged 2-12 months; RR  $\geq 40$  BPM for children aged 1-5 years, and RR  $\geq 30$  BPM for children above 5 years old) independent of fever and crying
- ii) Oxygen saturation  $\leq 92\%$  on finger pulse oximeter taken at rest
- iii) Labored breathing (moaning, nasal fluttering, and infrasternal, supraclavicular and intercostal retraction), cyanosis, and intermittent apnea
- iv) Lethargy and convulsion
- v) Difficulty feeding and signs of dehydration

#### Critical cases

Cases meeting any of the following criteria:

- i) Respiratory failure and requiring mechanical ventilation
- ii) Shock
- iii) With other organ failure that requires ICU care

## METHOD DETAILS

### Virus amplification and sequencing

Virus genomes were generated by two different approaches, (i) untargeted metagenomic sequencing on the BGI MGISEQ-2000 (n = 63) and Illumina NextSeq (n = 4) sequencing platforms, and (ii) using version 1 of the ARTIC COVID-19 multiplex PCR primers (<https://artic.network/ncov-2019>), followed by nanopore sequencing on an ONT MinION (n = 45). Untargeted metagenomic sequencing was initially attempted as it is well suited to the characterization of a previously unknown virus. Subsequently, a protocol for sequencing SARS-CoV-2 using multiplex PCR with nanopore sequencing was made available, which showed good performance on samples with higher Ct values (as described below and in Table S1.3). Thereafter, most clinical samples were sequenced using this latter approach. We report only those genomes for which we were able to generate > 50% genome coverage, and report only one genome per patient.

For metatranscriptomics, total RNAs were extracted from different types of samples by using QIAamp Viral RNA Mini Kit, followed by DNase treatment and purification with TURBO DNase and Agencourt RNAClean XP beads. Both the concentration and the quality of all isolated RNA samples were measured and checked with the Agilent Bioanalyzer 2100 and Qubit. For Illumina sequencing, libraries were prepared using the SMARTer Stranded Total RNA-Seq Kit v2 (according to the manufacturer's protocol starting with 10 ng total RNA. Briefly, purified RNA was first fragmented and converted to cDNA using reverse transcriptase. The ribosome cDNA was depleted by using ZapRv2 (mammalian-specific). The remaining cDNA was converted to double stranded DNA and subjected to end-repair, A-tailing, and adaptor ligation. The constructed libraries were amplified using 9-16 PCR cycles. Sequencing of metatranscriptome libraries was conducted on the Illumina NextSeq 550 SE 75 platform. For BGI sequencing, DNA-depleted and

purified RNA was used to construct the single-stranded circular DNA library with MGIEasy RNA Library preparation reagent set following manufacturer's protocol. Finally, 60fmol of PCR products were Unique Dual Indexed (UDI), circularized, and amplified by rolling circle replication (RCR) to generate DNA nanoball (DNBs)-based libraries. DNBs preps of clinical samples were sequenced on the MGISEQ-2000 platform.

For the multiplex PCR approach, we followed the general method of multiplex PCR as described in (<https://artic.network/ncov-2019>) (Quick et al., 2017). Briefly, the multiplex PCR was performed with two pooled primer mixture and the cDNA reverse transcribed with random primers was used as a template. After 35 rounds of amplification, the PCR products were collected and quantified, followed with end-repairing and barcoding ligation. Around 50 fmol of final library DNA was loaded onto the MinION. The nanopore sequencing platform takes less than 24 hours to obtain 10Gb of sequencing data, achieving between 0.3–0.6 million reads per sample. The ARTIC bioinformatics pipeline for COVID (<https://artic.network/ncov-2019>) was used to generate consensus sequences and call single nucleotide changes relative to the reference sequence. SNP differences were sometimes observed when the same sample was sequenced using different sequencing approaches. These differences were random and not platform specific and, upon close inspection of the reads, most likely resulted from low coverage regions in the metagenomics data. Only the single highest-quality genome was retained per patient.

To test the precision and threshold of the multiplex PCR and nanopore sequencing method, we undertook a serial dilution experiment. Viral RNA was extracted from a cell strain of SARS-CoV-2. To mimic clinical samples with different viral loads, we diluted this viral RNA with SARS-CoV-2-negative RNA extracted from nasopharyngeal swab specimens. Viral loads were estimated using RT-PCR with serial diluted plasmid as a standard. At each dilution level we performed multiplex PCR and nanopore sequencing and assembly as per the approach above, except that reads were assembled against the consensus genome obtained from the original sample using metagenomic sequencing. As expected, relative virus load, % genome coverage, and average read depth decreased at higher dilutions. Genome coverage exceeded 75% for all except the final dilution (Table S1.3).

## QUANTIFICATION AND STATISTICAL ANALYSIS

### Virus genome assembly


Reference-based assembly of the metagenomic raw data was performed as follows. Illumina adaptors were removed, and reads were filtered for quality (q30 threshold and read length > 15nt) using Cutadapt 1.18 (Martin, 2011). The mapping of cleaned reads was performed against GenBank reference strain MN908947.3 using Bowtie2 (Langmead and Salzberg, 2012). Consensus sequences were generated using samtools 1.2 (Li et al., 2009). Sites were called at depth > = 3 if they matched the reference strain, or depth > = 5 if they differed from the reference, otherwise sites were denoted N. Ambiguity nucleotide codes were used if (i) the minor variant is observed at > 30% frequency and (ii) the minor variant is represented by 5 or more reads. Assembly of the nanopore raw data was performed using the ARTIC bioinformatic pipeline for COVID-19 with minimap2 (Li, 2018) and medaka (<https://github.com/nanoporetech/medaka>) for consensus sequence generation. For patient samples that were sequenced using both metagenomics and nanopore sequencing, we retained only the sequence with the highest genome coverage.

### Phylogenetic analysis

All available SARS-CoV-2 sequences (n = 323) on GISAID ([gisaid.org](https://gisaid.org)) on 13<sup>th</sup> March 2020 were downloaded. Sequences from GISAID that were error-rich, those which represented multiple sequences from the same patient, and those without a date of sampling were removed. Finally, the dataset was reduced by only retaining the earliest and most recently sampled sequences from epidemiologically linked outbreaks (e.g., the Diamond Princess cruise ship). The resulting dataset of 250 sequences therefore represents the global diversity of the virus while minimizing the impact of sampling bias. Sequences were aligned using MAFFT v7.4 (Kato and Standley, 2013) and manually inspected in Geneious v11.0.3 (<https://www.geneious.com>). The final alignment length was 29,923 nucleotides.

We used both the maximum likelihood (ML) and Bayesian coalescent methods to explore the phylogenetic structure of SARS-CoV-2. The ML phylogeny was estimated with PhyML (Guindon et al., 2010) using the HKY+ $\Gamma_4$  substitution model (Hasegawa et al., 1985) with gamma-distributed rate variation (Yang, 1994). Linear regression of root-to-tip genetic distance against sampling date indicated that the SARS-CoV-2 sequences evolve in clock-like manner ( $r = 0.592$ ) (Figure S3). The Bayesian coalescent tree analysis was undertaken with BEAST v1.10.4 (Ayes et al., 2012; Suchard et al., 2018), also using the HKY+ $\Gamma_4$  substitution model with gamma-distributed rate variation with an exponential population growth tree prior and a strict molecular clock, under a non-informative continuous-time Markov chain (CTMC) reference prior (Ferreira and Suchard 2008). Taxon sets were defined and used to estimate the posterior probability of monophyly and the posterior distribution of the tMRCA of observed phylogenetic clusters A-E (Table S1.2). Two independent chains were run for 100 million states and parameters and trees were sampled every 10,000 states. Upon completion, chains were combined using LogCombiner after removing 10% of states as burn-in and convergence was assessed with Tracer (Rambaut et al., 2018). The maximum clade credibility (MCC) tree was inferred from the Bayesian posterior tree distribution using TreeAnnotator, and visualized with figtreejs-react (<https://github.com/jtmccr1/figtreejs-react>). Monophyly and tMRCA (time to the most recent common ancestor) statistics were calculated for each taxon set from the posterior tree distribution.


## Supplemental Figures



**Figure S1. Time Series of Reported Cases and Sample Collection Dates, Related to Figure 1**


(A) Time series of the 1388 laboratory-confirmed COVID-19 cases in Guangdong until 19<sup>th</sup> March, by date of onset of illness. Cases are classified according to their likely exposure histories (see inset). The solid line indicates the cumulative number of cases and the dashed lines indicate the date the first case was detected in Guangdong (19<sup>th</sup> January) and the shutdown of travel from Wuhan (23<sup>rd</sup> January). (B) Time series of the 53 SARS-CoV-2 genomes we report, by collection date. Genomes are classified according to patients' likely exposure history. The collection dates of 17 previously released genomes sampled from patients in Guangdong are also shown.






**Figure S2. Plots of SARS-CoV-2 Genome Coverage against RT-PCR Ct Value and the Number of Mapped Reads for 104 Sequencing Runs Performed on 79 Clinical Samples, Related to Figure 2**

Plots of SARS-CoV-2 genome coverage against RT-PCR Ct Value (A) and the number of mapped reads (B). Each sequence is colored by sequencing approach: blue = multiplex PCR nanopore sequencing, green = BGI metagenomic sequencing, orange = Illumina metagenomic sequencing. Open circles indicate sequences that were not reported here or used in phylogenetic analyses, either because of insufficient coverage, or because a higher-quality sequence existed for the same patient.




**Figure S3. Root-to-Tip Genetic Distance for 250 Sequences in the Maximum Likelihood Tree Plotted against Collection Date, Related to Figure 3**

The Pearson correlation coefficient between root-to-tip distance and collection date is displayed in the top-right corner ( $r = 0.592$ ). Sequences are colored by sampling location (Guangdong = red, other location = gray).



**Figure S4. Details of the Clusters (A–E) of Guangdong Genome Sequences, Related to Figure 3**

(A–E) Details of the clusters of Guangdong genome sequences. Extracts from the maximum-likelihood phylogeny are shown on the left and extracts from the maximum clade credibility (MCC) tree are shown on the right. Tip labels show GISAID accession number; those in red are from Guangdong and those in black are from other locations. Node bars on the MCC extracts indicate the 95% HPD interval of node ages. Nodes with posterior probability > 0.8 are labeled with a number and gray circle.



**Figure S5. Screenshots of the Online Tree Visualization Tool, Related to Figure 3**

The top image shows the 5 clusters A-E highlighted. The bottom image shows the genomes from Guangdong highlighted.